LCN2 and Duchenne muscular dystrophy: One study investigating the role of lipoclin-2 as a potential therapeutic target in Duchenne muscular dystrophy (DMD) -induced bone loss in mice reported that deleting Lcn2, (by downregulation or blocking its activity) attenuated the loss of bone associated with DMD.